Show simple item record

dc.contributor.authorZhang, Peng
dc.contributor.authorHuang, Yixian
dc.contributor.authorLiu, Hao
dc.contributor.authorMarquez, Rebecca T.
dc.contributor.authorLu, Jianqin
dc.contributor.authorZhao, Wenchen
dc.contributor.authorZhang, Xiaolan
dc.contributor.authorGao, Xiang
dc.contributor.authorLi, Jiang
dc.contributor.authorVenkataramanan, Raman
dc.contributor.authorXu, Liang
dc.contributor.authorLi, Song
dc.date.accessioned2017-05-10T17:49:49Z
dc.date.available2017-05-10T17:49:49Z
dc.date.issued2014-08
dc.identifier.citationZhang, P., Huang, Y., Liu, H., Marquez, R., Lu, J., Zhao, W., … Li, S. (2014). A PEG-Fmoc conjugate as a nanocarrier for paclitaxel. Biomaterials, 35(25), 7146–7156. http://doi.org/10.1016/j.biomaterials.2014.04.108en_US
dc.identifier.urihttp://hdl.handle.net/1808/24073
dc.description.abstractWe report here that a simple, well-defined, and easy-to-scale up nanocarrier, PEG5000-lysyl-(α-Fmoc-ε-t-Boc-lysine)2 conjugate (PEG-Fmoc), provides high loading capacity, excellent formulation stability and low systemic toxicity for paclitaxel (PTX), a first-line chemotherapeutic agent for various types of cancers. 9-Fluorenylmethoxycarbonyl (Fmoc) was incorporated into the nanocarrier as a functional building block to interact with drug molecules. PEG-Fmoc was synthesized via a three-step synthetic route, and it readily interacted with PTX to form mixed nanomicelles of small particle size (25–30 nm). The PTX loading capacity was about 36%, which stands well among the reported micellar systems. PTX entrapment in this micellar system is achieved largely via an Fmoc/PTX π-π stacking interaction, which was demonstrated by fluorescence quenching studies and 13C-NMR. PTX formulated in PEG-Fmoc micelles demonstrated sustained release kinetics, and in vivo distribution study via near infrared fluorescence imaging demonstrated an effective delivery of Cy5.5-labled PTX to tumor sites. The maximal tolerated dose for PTX/PEG-Fmoc (MTD > 120 mg PTX/kg) is higher than those for most reported PTX formulations, and in vivo therapeutic study exhibited a significantly improved antitumor activity than Taxol, a clinically used formulation of PTX. Our system may hold promise as a simple, safe, and effective delivery system for PTX with a potential for rapid translation into clinical study.en_US
dc.publisherElsevieren_US
dc.rightsThis article is available under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND 3.0) License.en_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/en_US
dc.subjectMicelleen_US
dc.subject9-Fluorenylmethoxycarbonylen_US
dc.subjectDrug-carrier interactionen_US
dc.subjectDrug deliveryen_US
dc.subjectPaclitaxelen_US
dc.subjectCancer therapyen_US
dc.titleA PEG-Fmoc conjugate as a nanocarrier for paclitaxelen_US
dc.typeArticleen_US
kusw.kuauthorLiu, Hao
kusw.kuauthorMarquez, Rebecca
kusw.kuauthorXu, Liang
kusw.kudepartmentMolecular Biosciences and Radiation Oncologyen_US
dc.identifier.doi10.1016/j.biomaterials.2014.04.108en_US
kusw.oaversionScholarly/refereed, author accepted manuscripten_US
kusw.oapolicyThis item meets KU Open Access policy criteria.en_US
dc.identifier.pmidPMC4102141en_US
dc.rights.accessrightsopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

This article is available under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND 3.0) License.
Except where otherwise noted, this item's license is described as: This article is available under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND 3.0) License.